XFOR logo

X4 Pharmaceuticals, Inc.

XFOR
Healthcare|Biotechnology|US
$3.18
+0.11 (+3.58%)
DCF Value
$20.28
Tangible Book / Share
$0.86
Cash / Share
$1.48
Next Earnings Report
Mar 16, 2027
EPS est. -$0.22 · Revenue est. $2.7M
Financing Filings (last 12 months)
1
Shelf registrations / offering prospectuses — latest May 6, 2026 (S-3). Possible dilution.

Upcoming Data Readouts (1)

Sep 2027
Est. completion
P3Neutropenia
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
NCT06056297n=176

Recent Press Releases

X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 4, 2026 · GlobeNewsWire
X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026
Nov 3, 2026 · GlobeNewsWire
X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day
Oct 29, 2026 · GlobeNewsWire
X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
Oct 9, 2026 · GlobeNewsWire
X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
Oct 8, 2026 · GlobeNewsWire
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 1, 2026 · GlobeNewsWire
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
Sep 9, 2026 · GlobeNewsWire
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
Sep 8, 2026 · GlobeNewsWire
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 1, 2026 · GlobeNewsWire

SEC Filings (85)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 4, 202610-QQuarterly reportDocumentIndex
Oct 29, 20268-KMaterial eventDocumentIndex
Oct 8, 20268-KMaterial eventDocumentIndex
Oct 7, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Sep 21, 2026SC 13GPassive 5%+ stakeDocumentIndex
Sep 9, 20268-KMaterial eventDocumentIndex
Sep 8, 20268-KMaterial eventDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 6, 202610-QQuarterly reportDocumentIndex
Jul 30, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 1, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 14, 2026EFFECTDocumentIndex
May 13, 20268-K/AMaterial eventDocumentIndex
May 12, 20268-KMaterial eventDocumentIndex
May 6, 2026S-3Shelf registrationDocumentIndex
May 6, 202610-QQuarterly reportDocumentIndex
Mar 20, 2026ARSAnnual report to holdersDocumentIndex
Mar 20, 2026DEFA14AProxy / shareholder voteDocumentIndex
Mar 20, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 18, 2026S-8Employee stock planDocumentIndex
Mar 17, 202610-KAnnual reportDocumentIndex
Mar 6, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 12, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 5, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 14, 2025SC 13GPassive 5%+ stakeDocumentIndex
Nov 7, 2025SC 13GPassive 5%+ stakeDocumentIndex
Nov 5, 202510-QQuarterly reportDocumentIndex
Nov 5, 20258-KMaterial eventDocumentIndex
Nov 3, 2025SC 13GPassive 5%+ stakeDocumentIndex
Oct 29, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Oct 27, 20258-KMaterial eventDocumentIndex
Oct 24, 2025424B5Offering prospectusDocumentIndex